FOXM1 Inhibition Enhances the Therapeutic Outcome of Lung Cancer Immunotherapy by Modulating PD‐L1 Expression and Cell Proliferation

FOXM1 Inhibition Enhances the Therapeutic Outcome of Lung Cancer Immunotherapy by Modulating PD‐L1 Expression and Cell Proliferation

Abstract Programmed death‐ligand 1 (PD‐L1) is a major target to cancer immunotherapy, and anti‐PD‐L1 and anti‐PD‐1 antibody‐mediated immunotherapy are being increasingly used. However, immune checkpoint inhibitors (ICIs) are ineffective in treating large tumors and cause various immune‐related adver...

Full description

Bibliographic Details
Main Authors: Hamadi Madhi, Jeon‐Soo Lee, Young Eun Choi, Yan Li, Myoung Hee Kim, Yongdoo Choi, Sung‐Ho Goh
Format: Article
Language:English
Published: Wiley 2022-10-01
Series:Advanced Science
Subjects:
forkhead box protein M1
immunotherapy
lung cancer
programmed death‐ligand 1
thiostrepton
Online Access:https://doi.org/10.1002/advs.202202702

Internet

https://doi.org/10.1002/advs.202202702

Similar Items